TransMedics Group, Inc. $TMDX Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. lowered its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 1.7% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,574,996 shares of the company’s stock after selling 60,923 shares during the quarter. Vanguard Group Inc. owned approximately 10.57% of TransMedics Group worth $240,526,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. NBC Securities Inc. acquired a new position in TransMedics Group during the 1st quarter valued at approximately $25,000. Hager Investment Management Services LLC boosted its position in TransMedics Group by 38.3% during the 1st quarter. Hager Investment Management Services LLC now owns 740 shares of the company’s stock valued at $50,000 after purchasing an additional 205 shares during the period. CWM LLC boosted its position in TransMedics Group by 20.1% during the 1st quarter. CWM LLC now owns 925 shares of the company’s stock worth $62,000 after acquiring an additional 155 shares during the period. GAMMA Investing LLC boosted its position in TransMedics Group by 551.7% during the 1st quarter. GAMMA Investing LLC now owns 1,564 shares of the company’s stock worth $105,000 after acquiring an additional 1,324 shares during the period. Finally, Sava Infond d.o.o. boosted its position in TransMedics Group by 46.7% during the 1st quarter. Sava Infond d.o.o. now owns 2,200 shares of the company’s stock worth $148,000 after acquiring an additional 700 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

Insider Transactions at TransMedics Group

In other news, Director David Weill sold 732 shares of the business’s stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $123.88, for a total transaction of $90,680.16. Following the sale, the director directly owned 12,134 shares of the company’s stock, valued at $1,503,159.92. The trade was a 5.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Edward M. Basile sold 5,000 shares of the business’s stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $126.45, for a total value of $632,250.00. Following the sale, the director directly owned 2,866 shares in the company, valued at $362,405.70. This trade represents a 63.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 6,418 shares of company stock valued at $818,833 over the last three months. Company insiders own 7.00% of the company’s stock.

TransMedics Group Stock Down 1.5%

TMDX opened at $125.65 on Tuesday. The stock’s fifty day moving average is $123.38 and its 200-day moving average is $100.34. The company has a market capitalization of $4.28 billion, a PE ratio of 65.10 and a beta of 2.09. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.17 and a current ratio of 9.86. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $177.37.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.44. The company had revenue of $157.37 million for the quarter, compared to analyst estimates of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%. TransMedics Group’s revenue for the quarter was up 37.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.35 earnings per share. On average, equities analysts predict that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on TMDX. Wall Street Zen upgraded TransMedics Group from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Piper Sandler reiterated an “overweight” rating and set a $145.00 price target (up previously from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research report on Tuesday, June 17th. Morgan Stanley boosted their price target on TransMedics Group from $115.00 to $123.00 and gave the stock an “equal weight” rating in a research report on Friday, August 1st. Finally, Canaccord Genuity Group boosted their price objective on TransMedics Group from $129.00 to $142.00 and gave the stock a “buy” rating in a research note on Tuesday, July 15th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, TransMedics Group has an average rating of “Moderate Buy” and a consensus price target of $123.00.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.